Shots:

• The LANDSCAPE and NEST clinical development program evaluates the efficacy and safety of zuranolone in patients with MDD and PPD. The presentations also include data from the P-III WATERFALL & open-label SHORELINE study for MDD
• The studies showed a reduction in depressive symptoms including improvements in depressive moods & rapid onset of significant effect @3 day. The therapy showed a consistent safety profile in the totality of clinical data
• In pooled analyses from the LANDSCAPE and NEST programs of SF-36v2- the therapy showed a rapid improvement in QoL- functioning- and well-being domains @15 day and across all domains @42 day

| Ref: Biogen | Image: Biogen